DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
Saved in:
| Title: | DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. |
|---|---|
| Authors: | Johnstone CN; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia., Osellame LD; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Cao Z; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia., McDonald AF; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia., Rigopoulos A; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Burvenich IJG; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Wichmann CW; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia., Guo N; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia., Ivashkevich AN; Telix Pharmaceuticals, North Melbourne, Victoria, Australia., Wheatcroft MP; Telix Pharmaceuticals, North Melbourne, Victoria, Australia., Yan EB; Telix Pharmaceuticals, North Melbourne, Victoria, Australia., Zimmermann A; Merck KGaA, Darmstadt, Germany., Zenke FT; EMD Serono, Billerica, Massachusetts; and., Sirrenberg C; Merck KGaA, Darmstadt, Germany., Scott FE; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Scott AM; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; andrew.scott@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia.; Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. |
| Source: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2025 Mar 03; Vol. 66 (3), pp. 385-390. Date of Electronic Publication: 2025 Mar 03. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1535-5667 |
|---|---|
| DOI: | 10.2967/jnumed.124.268695 |
